 |
|
|
| |
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
|
| |
| |
IDSA Oct 21-24 Wash DC
Oct 19, 2026
- Analyses of Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg) Examine Outcomes in People with HIV and Selected Comorbidities or Renal Impairment -
- Real-World Evidence Provides Insight into Early U.S. Adoption of Yeztugo® (lenacapavir) for HIV PrEP -
- Phase 1b Data Highlight Virologic Efficacy, Safety and Tolerability of Investigational GS-1179 for Recurrent Genital Herpes -
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its HIV and antiviral research and development programs at IDWeek 2026, taking place October 21-24 in Washington, D.C. The 28 presentations, including two oral presentations, will feature research in HIV treatment, HIV prevention and new insights into broader experiences of people living with HIV, as well as emerging antiviral programs.
"We remain committed to advancing options for people affected by HIV and other serious diseases, as evidenced by the breadth of our research and antiviral pipeline," said Jared Baeten, MD, PhD, Senior Vice President, Clinical Development, Virology Therapeutic Area Head, Gilead Sciences. "These findings span clinical research and real-world evidence, deepening our understanding of evolving needs and informing innovations that have the potential to make a meaningful difference for the communities we serve."
HIV Treatment Research
New analyses from the Phase 3 ARTISTRY-1 and ARTISTRY-2 Studies will provide further insights into the safety and efficacy of Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily, single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed, including those on complex regimens. New ARTISTRY-1 sub-analyses will provide insights into treatment outcomes among trial participants with comorbidities like dyslipidemia, hypertension, diabetes mellitus and renal impairment, building on data from the oldest study population in a Phase3 registrational trial for HIV-1 treatment to date. Findings from ARTISTRY-2 will examine metabolic and safety outcomes among people with HIV with selected baseline comorbidities.
Additional treatment research will examine virologic effectiveness, resistance and strategies for restarting antiretroviral therapy following interruptions in care, including studies in historically under-resourced communities and analyses of treatment patterns in real-world settings.
Data from the Phase 4 ACCELERATE Implementation Study will be presented on Biktarvy®(bictegravir/emtricitabine/tenofovir alafenamide, B/F/TAF), examining rapid antiretroviral therapy (ART) restart for people with HIV returning to care.
HIV Prevention Research
Gilead will present research examining early real-world adoption of twice-yearly Yeztugo® (lenacapavir) for HIV pre-exposure prophylaxis (PrEP) in the United States during the first nine months following approval by the U.S. Food and Drug Administration (FDA). Yeztugo is the only FDA-approved twice-yearly option for people who need or want PrEP.
Additional studies will examine factors that influence PrEP access, uptake and implementation, including provider education, linkage to prevention services, cost sharing and the potential economic and public health impact of expanded HIV prevention.
Herpes Simplex Virus (HSV) Research
Gilead will also present final results from a Phase 1b Study of Investigational GS-1179, an oral, long-acting herpes simplex virus (HSV) helicase-primase inhibitor being developed for suppression of recurrent genital herpes. The presentations will highlight findings on virologic efficacy, safety and tolerability.
https://www.gilead.com/news/news-details/2026/gilead-to-present-new-data-across-hiv-and-emerging-antiviral-research-at-idweek-2026
|
| |
|
|
|
|
|
